Clozapine-induced eosinophilia: A case report
- PMID: 37667744
- PMCID: PMC10475262
- DOI: 10.1177/2050313X231195961
Clozapine-induced eosinophilia: A case report
Abstract
Schizophrenia is a chronic neuropsychiatric illness defined by the appearance of positive, and negative symptoms and/or cognitive impairment. Antipsychotic drugs are predominantly used in the treatment of psychotic disorders, but not all patients with schizophrenia respond to every antipsychotic medication. Clozapine is one of the best atypical antipsychotics and is highly effective in treating treatment-resistant schizophrenia. Evidence suggests that clozapine appears to be effective in lowering the risk of suicide, extrapyramidal side effects, and relapse in patients with schizophrenia. Per contra, clozapine is not the first-line treatment due to its unalterable aftereffects such as agranulocytosis, metabolic syndrome, seizures, and rarely, eosinophilia. Eosinophilia can be life-threatening. Eosinophils infiltrate different tissues and cause inflammation in multiple organs causing end-organ damage. The current study aimed to report the incidence of eosinophilia associated with clozapine use in patients with schizophrenia. Literature on clozapine-induced eosinophilia is relatively scarce. Understanding the progression and management of clozapine-induced eosinophilia and its end-organ effects is imperative. While there is insufficient data about the guidelines in the management of clozapine-induced eosinophilia, this study contributes to understanding the patterns of the disease progression with clozapine dosage. A case study was done on a patient with schizophrenia and autistic spectrum disorder who was on clozapine. Data on how eosinophil levels varied with clozapine dosing was analyzed and documented. The evidence of clozapine dosage affecting eosinophil and C-reactive protein levels in this patient was summarized in a table and a narrative review.
Keywords: Clozapine; antipsychotics; case report; eosinophilia.
© The Author(s) 2023.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
Similar articles
-
Clozapine-Induced Eosinophilia: a Case Report.Rev Colomb Psiquiatr (Engl Ed). 2023 Apr-Jun;52(2):161-164. doi: 10.1016/j.rcpeng.2021.04.008. Rev Colomb Psiquiatr (Engl Ed). 2023. PMID: 37500239 English, Spanish.
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
Clozapine-Induced Eosinophilia: a Case Report.Rev Colomb Psiquiatr (Engl Ed). 2021 Jun 21:S0034-7450(21)00080-9. doi: 10.1016/j.rcp.2021.04.004. Online ahead of print. Rev Colomb Psiquiatr (Engl Ed). 2021. PMID: 34167790 English, Spanish.
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
-
Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.Isr J Psychiatry Relat Sci. 2007;44(1):54-6. Isr J Psychiatry Relat Sci. 2007. PMID: 17665812
References
-
- Kane JM, Agid O, Baldwin ML, et al.. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry 2019; 80(2): 2783. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials